lunes, 2 de mayo de 2016

Melanoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Melanoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute



National Cancer Institute

Melanoma Treatment–Health Professional Version (PDQ®)



SECTIONS

Changes to This Summary (04/15/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Revised text to state that cobimetinib is an orally available, small-molecule, selective MEK inhibitor that was approved by the U.S. Food and Drug Administration (FDA) in 2015 for use in combination with theBRAF inhibitor vemurafenib.
Revised text to state that in 2015, the combination of vemurafenib and cobimetinib was also approved by the FDA for patients with unresectable or metastatic melanomas that carry the BRAF V600E or V600K mutation. Published phase III data support improved progression-free survival of another combination of BRAF and MEKinhibitors versus BRAF inhibitor plus placebo: dabrafenib plus trametinib compared with dabrafenib plus placebo. Overall survival (OS) data are immature.
Added Adjuvant therapy as a new subsection.
Added Immunotherapy as a new subsection.
Revised text of treatment options under clinical evaluation for patients with resectable stage III melanoma to include trials of adjuvant therapies that have shown improvement in OS in metastatic disease and trials of adjuvant therapies that target a known mutation, e.g., c-KIT.
Added intralesional therapy to the list of treatment options for unresectable stage III, stage IV, and recurrent melanoma.
Added Intralesional Therapy as a new subsection.
Revised text to state that cobimetinib is a small-molecule, selective MEK inhibitor that was approved by the FDA in 2015 for use in combination with the BRAF inhibitor vemurafenib.
Added text to include combinations of immunotherapy and targeted therapy as a treatment option under clinical evaluation.
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: April 15, 2016

No hay comentarios:

Publicar un comentario